The estimated Net Worth of Jonathan E Lim is at least $9.71 Milione dollars as of 13 February 2017. Jonathan Lim owns over 6,945 units of Halozyme Therapeutics stock worth over $7,740,477 and over the last 17 years Jonathan sold HALO stock worth over $1,966,690.
Sign up
Jonathan Lim HALO stock SEC Form 4 insiders trading
Jonathan has made over 18 trades of the Halozyme Therapeutics stock since 2007, according to the Form 4 filled with the SEC. Most recently Jonathan exercised 6,945 units of HALO stock worth $4,167 on 13 February 2017.
The largest trade Jonathan's ever made was selling 250,000 units of Halozyme Therapeutics stock on 20 March 2008 worth over $1,515,000. On average, Jonathan trades about 35,087 units every 142 days since 2007. As of 13 February 2017 Jonathan still owns at least 130,333 units of Halozyme Therapeutics stock.
You can see the complete history of Jonathan Lim stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jonathan Lim's mailing address?
Jonathan's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY RD., SUITE 17, SAN DIEGO, CA, 92121.
Insiders trading at Halozyme Therapeutics
Over the last 18 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay e Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
What does Halozyme Therapeutics do?
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
What does Halozyme Therapeutics's logo look like?
Complete history of Jonathan Lim stock trades at Halozyme Therapeutics
Halozyme Therapeutics executives and stock owners
Halozyme Therapeutics executives and other stock owners filed with the SEC include:
-
Helen Torley,
President, Chief Executive Officer, Director -
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.,
Pres, CEO & Director -
Elaine D. Sun,
Sr. VP & CFO -
Dr. Michael J. LaBarre,
Sr. VP & Chief Technical Officer -
Connie Matsui,
Independent Chairman of the Board -
Jeffrey Henderson,
Independent Director -
Kenneth Kelley,
Independent Director -
Matthew Posard,
Independent Director -
Bernadette Connaughton,
Independent Director -
Jean-Pierre Bizzari,
Independent Director -
James Daly,
Independent Director -
Al Kildani,
Vice President, Investor Relations & Corporate Communications -
Elaine Sun,
Chief Financial Officer, Senior Vice President -
Todd Butler,
Chief of Staff to the CEO, VP & Head of Project Management -
Dr. Steve Knowles B.S.,
Chief Medical Officer -
William J. Fallon,
Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances -
Amy Marinne Fox,
VP of HR -
Mark Snyder,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Albert S. Kildani,
VP of Investor Relations & Corp. Communications -
Ed Gemo,
VP, Chief Information & Security Officer -
Athena Countouriotis,
SVP and Chief Medical Officer -
Kathryn E Falberg,
Director -
Mark J Gergen,
SVP, Chief Operating Officer -
Mark Howard Snyder,
SVP, CHIEF LEGAL OFFICER -
Randal J Kirk,
Director -
Harry J Leonhardt,
SVP, GC and CCO -
Alison A. Armour,
SVP, Research & Development -
John Stuart Patton,
Director -
Robert Engler,
Director -
David A Ramsay,
Secretary, CFO -
William J Fallon,
VP-Manufacturing and Operation -
James P Shaffer,
VP & Chief Commercial Officer -
Jean I Liu,
VP & General Counsel -
Gregory Ian Frost,
VP and Chief Scientific Off. -
H. Michael Shepard,
VP, Chief Scientific Officer -
Kurt A Gustafson,
Vice President and CFO -
Steven T Thornton,
Director -
Jonathan E Lim,
President, CEO -
Richard C Yocum,
VP-Clinical Development -
Jonathan A Leff,
VP, Chief Medical Officer -
Robert J Little,
VP-Chief Commercial Officer -
Don A Kennard,
Vice President, Regulatory Aff -
Matthew Hooper,
Vice Pres & General Counsel -
Benjamin Hickey,
SVP, Chief Commerical Officer -
Laurie Stelzer,
SVP, Chief Financial Officer -
Mahesh Krishnan,
-
Masaru Matsuda,
SVP, General Counsel -
Akiko Moni Miyashita,
-
Michael J. La Barre,
SVP, CHIEF TECHNICAL OFFICER -
Nicole La Brosse,
SVP, CHIEF FINANCIAL OFFICER -
Barbara Gayle Duncan,